Company Directory - Iovance Biotherapeutics, Inc.
Company Details - Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
WebsiteSan Carlos, United States
ISIN: US4622601007
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on pioneering cell therapies for cancer treatment, with an emphasis on tumor-infiltrating lymphocyte (TIL) therapies.
CCI Score
CCI Score: Iovance Biotherapeutics, Inc.
-24.95
0.01%
Latest Event
Iovance Biotherapeutics Lobbying Spending in 2023
In 2023, Iovance Biotherapeutics spent $170,000 on lobbying activities, a move that raises concerns about the company leveraging its influence to sway policy in ways that may undermine democratic processes and enable authoritarian practices.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
ACCOMPLICE
Iovance Biotherapeutics, Inc. is currently rated as an Accomplice.
Latest Events
- DEC312023
In 2023, Iovance Biotherapeutics spent $170,000 on lobbying activities, a move that raises concerns about the company leveraging its influence to sway policy in ways that may undermine democratic processes and enable authoritarian practices.
-40
Political Contributions and Lobbying Efforts
March 26
Iovance Biotherapeutics' lobbying expenditure of $170,000 in 2023 suggests an active effort to influence federal policy, raising red flags among anti-fascist observers concerned about corporate interference in democratic processes. Such spending is often seen as a mechanism for advancing special interests that may support policies aligned with authoritarian tendencies.
- DEC312022
In 2022, Iovance Biotherapeutics spent $880,000 on lobbying efforts, which raises concerns over corporate attempts to influence public policy and potentially bolster authoritarian practices.
-30
Political Contributions and Lobbying Efforts
March 26
Iovance Biotherapeutics' expenditure of $880,000 on lobbying in 2022 suggests active efforts to sway policy decisions. Such intensive lobbying raises concerns about the company's role in influencing government actions in ways that could indirectly support authoritarian or undemocratic practices.
- DEC312022
An analysis of OpenSecrets data highlights Iovance Biotherapeutics' historical engagement in lobbying, raising concerns from an anti-fascist perspective about corporate efforts to influence policy. Although the company has not reported lobbying on specific bills in 2024, its long-term presence in political lobbying is seen as problematic.
-20
Political Contributions and Lobbying Efforts
March 26
The OpenSecrets profile shows a longstanding pattern of lobbying by Iovance Biotherapeutics, a practice which can be used to shape policy in ways that favor corporate interests over democratic processes. Even though the company has not targeted specific legislation in 2024, the continued engagement in lobbying activities is concerning from the perspective of fostering undue corporate influence in politics and potentially contributing to authoritarian governance.
Alternatives
Cambridge, USA
-43.03
Corporation
0.00
Corporation
-29.73
Corporation
0.00
Corporation
-38.49
Somerset, United States
1.18
Cambridge, United States
0.27
Menlo Park, United States
-49.80
Thousand Oaks, USA
13.63
Mainz, Germany
-6.57
Industries
- 325414
- Biological Product (except Diagnostic) Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 621511
- Medical Laboratories